Placebo News and Research

RSS

NIH's candidate vaccine safe in treating dengue

A candidate dengue vaccine developed by scientists at the National Institutes of Health (NIH) has been found to be safe and to stimulate a strong immune response in most vaccine recipients, according to results from an early-stage clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH. The trial results were published online on January 17 in the Journal of Infectious Diseases.

23 Jan 2013

Novartis receives FDA approval for Exjade to treat chronic iron overload in NTDT patients

The U.S. Food and Drug Administration today expanded the approved use of Exjade (deferasirox) to treat patients ages 10 years and older who have chronic iron overload resulting from a genetic blood disorder called non-transfusion-dependent thalassemia (NTDT).

23 Jan 2013

Multiple vascular benefits in salt restriction

Restricting salt intake reverses vascular endothelial dysfunction in people with moderately increased blood pressure, shows a randomized study published in the Journal of the American College of Cardiology.

22 Jan 2013

Dutasteride decreases risk of biopsy detectable prostate cancer by 22.8%

The four-year REDUCE (REduction by DUtasteride of prostate Cancer Events) clinical study evaluated prostate cancer risk reduction in men taking dutasteride, a 5-alpha-reductase inhibitor (5ARI) typically used to treat enlarged prostate.

22 Jan 2013

FDA approves Ampio’s IND for Optina for treatment of diabetic macular edema

Ampio Pharmaceuticals, Inc. announced today that the FDA has accepted the Company's IND for Optina™ for the treatment of diabetic macular edema (DME). Ampio plans to commence enrollment in a clinical trial in the first quarter of 2013. The FDA granted Optina™ 505(b)(2) status in July, 2012. Drugs designated under this pathway can be approved on a single trial.

22 Jan 2013

FDA approves Allergan’s BOTOX to treat overactive bladder

Allergan, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved BOTOX (onabotulinumtoxinA) for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and frequency in adults who have had an inadequate response to or are intolerant of an anticholinergic medication.

19 Jan 2013

Allergan receives FDA approval for Botox to treat overactive bladder

The U.S. Food and Drug Administration today expanded the approved use of Botox (onabotulinumtoxinA) to treat adults with overactive bladder who cannot use or do not adequately respond to a class of medications known as anticholinergics.

18 Jan 2013

Macular pigment screening: an interview with Jaquie Finn, Product Line Manager at Elektron Technology

AMD is the leading cause of vision loss in anyone over 50 and globally in 2010 it was estimated to cost $340 billion to treat AMD. The costs are set to spiral over the next 20 years and really over burden the healthcare system unless people start to take preventative action.

18 Jan 2013

Boehringer Ingelheim initiates enrollment in Phase III IFN-free HCV trial

Today, Boehringer Ingelheim announced that the first patients have been enrolled in the company's pivotal Phase III interferon (IFN)-free hepatitis C (HCV) clinical trial programme, HCVerso.

18 Jan 2013

Children's Oakland recruits patients for deferiprone clinical trial to treat PKAN

A groundbreaking, international clinical trial of an iron chelation drug, deferiprone, to treat the rare and devastating neurodegenerative disease, pantothenate kinase-associated neurodegeneration (PKAN), began last month at the trial's only North American site, Children's Hospital & Research Center Oakland.

17 Jan 2013

Underestimating cough duration may skew antibiotic perceptions

US researchers suggest that one reason patients request antibiotics for respiratory infections is that they greatly underestimate how long it usually takes for acute cough illness to resolve.

17 Jan 2013

Top-line results from Amgen’s Aranesp Phase 3 trial on heart failure and anemia

Amgen today announced top-line results of the Phase 3 Aranesp (darbepoetin alfa) RED-HF (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial.

17 Jan 2013

Protein Sciences receives FDA approval for Flublok vaccine

The U.S. Food and Drug Administration today announced that it has approved Flublok, the first trivalent influenza vaccine made using an insect virus (baculovirus) expression system and recombinant DNA technology. Flublok is approved for the prevention of seasonal influenza in people 18 through 49 years of age.

16 Jan 2013